{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rosenblat TL"],"funding":["NCI NIH HHS","NIH","Lymphoma Foundation, and Actinium Pharmaceuticals, Inc."],"pagination":["2030-2037"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9106874"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(10)"],"pubmed_abstract":["<h4>Purpose</h4>The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab.<h4>Patients and methods</h4>Eighteen patients (median age, 64 years; range, 45-80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg.<h4>Results</h4>The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppre"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab."],"pmcid":["PMC9106874"],"funding_grant_id":["RO1 55349","P30 CA008748","P01 CA033049","R01 CA055349","PO1 CA33049","R35 CA241894"],"pubmed_authors":["Carrasquillo JA","Larson SM","McDevitt MR","Park JH","Rosenblat TL","Scheinberg DA","Maslak PG","Pandit-Taskar N","Douer D","Cicic D","Frattini MG","Jurcic JG"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.","description":"<h4>Purpose</h4>The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab.<h4>Patients and methods</h4>Eighteen patients (median age, 64 years; range, 45-80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg.<h4>Results</h4>The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppre","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-05-29T16:11:45.459Z","creation":"2025-04-04T09:32:15.775Z"},"accession":"S-EPMC9106874","cross_references":{"pubmed":["35247915"],"doi":["10.1158/1078-0432.ccr-21-3712","10.1158/1078-0432.CCR-21-3712"]}}